4305 Investors following Jubilant Life. Share this News with them.
0
Like this story, share it with millions of investors on M3
Buy Jubilant Org, target of Rs 397: India Capital Markets
India Capital Markets has maintained its buy rating on Jubilant Organosys with a target of Rs 397. Jubilant having started as a speciality chemical player, has rapidly expanded its presence through out the value chain of pharma life-cycle driven both organically as well as in-organically.
India Capital Markets has maintained its buy rating on Jubilant Organosys with a target of Rs 397 in its October 15, 2008 research report. "Jubilant having started as a speciality chemical player, has rapidly expanded its presence through out the value chain of pharma life-cycle driven both organically as well as in-organically. Its recent acquisitions in the CRAMS space like Hollister-stier in US and Draxis in Canada has consolidated its position in the regulated markets. With its wellchanneled network into the regulated markets and its expanded capabilities in the CRAMS."
"Sales were up 52% YoY at Rs 9,405 million, driven by the Pharma & Life Sciences business which grew 59% YoY at Rs 5,858 million. Pharma & Life Sciences business contributed 62% of total sales in Q2FY09 (60% in Q2FY08). We maintain a Buy rating with a price target of Rs 397 per share (upside of 116%)," says India Capital Markets' research report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
To read the full report click on the attachment......
